Pharsight

Stiolto Respimat patents expiration

STIOLTO RESPIMAT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7491719 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments
Nov, 2023

(4 months ago)

US7056916 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Dec, 2023

(3 months ago)

US7220742 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(1 year, 1 month from now)

US7727984 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Jan, 2027

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8044046 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Nov, 2023

(4 months ago)

US7786111 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Nov, 2023

(4 months ago)

US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(4 months from now)

US7284474

(Pediatric)

BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Feb, 2025

(10 months from now)

US8034809 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(1 year, 1 month from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(1 year, 1 month from now)

US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Oct, 2026

(2 years from now)

US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2027

(3 years from now)

US7396341

(Pediatric)

BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Apr, 2027

(3 years from now)

US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2028

(3 years from now)

US7837235

(Pediatric)

BOEHRINGER INGELHEIM Device for clamping a fluidic component
Sep, 2028

(4 years from now)

US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Oct, 2030

(6 years from now)

Stiolto Respimat is owned by Boehringer Ingelheim.

Stiolto Respimat contains Olodaterol Hydrochloride; Tiotropium Bromide.

Stiolto Respimat has a total of 16 drug patents out of which 4 drug patents have expired.

Expired drug patents of Stiolto Respimat are:

  • US8044046
  • US7786111
  • US7491719
  • US7056916

Stiolto Respimat was authorised for market use on 21 May, 2015.

Stiolto Respimat is available in spray, metered;inhalation dosage forms.

Stiolto Respimat can be used as treatment of respiratory complaints, treatment of copd.

The generics of Stiolto Respimat are possible to be released after 16 October, 2030.

Drugs and Companies using OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE ingredient

Market Authorisation Date: 21 May, 2015

Treatment: Treatment of copd; Treatment of respiratory complaints

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage

STIOLTO RESPIMAT family patents

Family Patents